PolyPid (NASDAQ:PYPD – Get Free Report) and Nemaura Medical (NASDAQ:NMRD – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, valuation, analyst recommendations, dividends and institutional ownership.
Profitability
This table compares PolyPid and Nemaura Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| PolyPid | N/A | -572.69% | -110.25% |
| Nemaura Medical | N/A | N/A | -142.69% |
Analyst Ratings
This is a summary of current recommendations for PolyPid and Nemaura Medical, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| PolyPid | 0 | 0 | 1 | 0 | 3.00 |
| Nemaura Medical | 0 | 0 | 1 | 0 | 3.00 |
Earnings and Valuation
This table compares PolyPid and Nemaura Medical’s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| PolyPid | N/A | N/A | -$23.86 million | ($12.64) | -0.34 |
| Nemaura Medical | $80,000.00 | 24.51 | -$14.14 million | ($0.39) | -0.12 |
Nemaura Medical has higher revenue and earnings than PolyPid. PolyPid is trading at a lower price-to-earnings ratio than Nemaura Medical, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
26.5% of PolyPid shares are held by institutional investors. Comparatively, 4.4% of Nemaura Medical shares are held by institutional investors. 24.7% of PolyPid shares are held by insiders. Comparatively, 41.6% of Nemaura Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Risk & Volatility
PolyPid has a beta of 1.31, meaning that its stock price is 31% more volatile than the S&P 500. Comparatively, Nemaura Medical has a beta of -0.01, meaning that its stock price is 101% less volatile than the S&P 500.
Summary
Nemaura Medical beats PolyPid on 6 of the 9 factors compared between the two stocks.
About PolyPid
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
About Nemaura Medical
Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.
Receive News & Ratings for PolyPid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PolyPid and related companies with MarketBeat.com's FREE daily email newsletter.
